Notice of Preliminary Results

RNS Number : 0412K

hVIVO plc

06 April 2018

 

For immediate release 7.00am: 6 April 2018

HVIVO PLC

("hVIVO" or the "Company")

 

Notice of Preliminary Results

hVIVO plc (AIM: HVO) will announce its audited preliminary results for the year ended 31 December 2017 on Thursday, 19 April 2018.

For further information please contact:

hVIVO plc	[phone]
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries	[phone]
Susan Flood
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK)	[phone]

Notes to Editors:

About hVIVO plc

hVIVO plc ("hVIVO") is developing a pioneering human-based analytical platform to accelerate drug discovery and development in airways diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

 

END

 

 

NORUGUMPCUPRPPA